|
|
| |
|
Pyroptosis is a lytic cell death caused by gasdermin (GSDM)-mediated pore-forming. Studies have revealed that antitumor immunity can be induced by GSDME-mediated pyroptosis. Certain chemotherapeutic agents induce pyroptosis through Caspase-3 / GSDME pathway. Oncolytic parapoxvirus also induces GSDME-mediated pyroptosis. The pyroptotic cells lead to passive secretion of HMGB1 which in turn triggers immunogenic cell death (ICD) and antitumor immunity. GSDME-mediated pyroptosis becomes an emerging strategy for cancer therapy.
arigo offers antibody panels for GSDME-mediated pyroptosis and inflammasome-dependent pyroptosis to facilitate the research of cancer-associated pyroptosis.
|
|
|
| |
|
|
|
|
| |
|
GSDME-mediated Pyroptosis Antibody Panel
(ARG30343)
|
| |
-
Includes Caspase-3 antibody for detecting both pro- and cleaved forms
-
Includes GSDME antibody for detecting both pro- and cleaved forms
-
Includes HMGB1 antibody for detecting lytic cell death
-
Works on human, mouse, and rat samples
|
| |
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
Immunogenic cell death (ICD) is sufficient to activate adaptive immune responses against tumor cells. A hallmark of ICD is the release of HMGB1 which promotes DC maturation, antigen presentation and subsequent CTL-mediated tumor cell killing. arigo offers comprehensive HMGB1 ELISA kits to facilitate the detection of ICD in human and mice.
|
|
|
|
|
|
|
| |
|
More antibody panels for Pyroptosis
|
|
|
| |
|
|
|
|
